Clinical trials
Inflammatory Breast Cancer clinical trials
Below are recruiting inflammatory breast cancer clinical trials, each written for real people, not researchers. We’re tracking 332 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07726342RecruitingPhase 2
Study of a new drug for advanced HER2-positive breast cancer
This study tests a new drug, SMP-656, for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if it can help shrink or control the cancer.
Hefei, AnhuiAges 18 years+ - NCT05292742RecruitingPhase 2
Continue targeted breast cancer therapy or switch to a new combo
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
Fuzhou, FujianAges 18–75 - NCT04836156RecruitingPhase 1/Phase 2
Personalized pre-surgery treatment for HER2-negative early breast cancer
This study tests a treatment plan chosen using lab drug testing on a patient’s tumor (in a dish). It may help improve outcomes for people with early breast cancer that is HER2-negative by matching therapy to what the tumor seems sensitive to.
BeijingAges 18–75 - NCT03150576RecruitingPhase 2/Phase 3
Before-surgery treatment for triple-negative or BRCA breast cancer
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Cambridge, CambridgeshireAges 16–70 - NCT05462457Recruiting
Tests adding a targeted approach for breast cancer with many involved nodes
This trial studies a treatment plan for early breast cancer that involves at least three suspicious lymph nodes on the ultrasound/imaging. It looks at whether a targeted technique—done before surgery with chemotherapy—can improve or guide care when surgery will remove the lymph nodes.
EssenAges 18 years+ - NCT05638594RecruitingPhase 2
Neoadjuvant drug study for hormone- and HER2-positive breast cancer
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
Shenyang, LiaoningAges 18–75 - NCT06000917RecruitingPhase 2
Study of combination therapy before surgery for ER+/HER2+ breast cancer
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT04050228Recruiting
Ultrasound test to tailor chemotherapy for breast cancer
This trial tests whether a special ultrasound measurement can help doctors choose the right chemotherapy plan during treatment for breast cancer. It may help avoid under- or over-treatment by adjusting care based on the ultrasound results.
Toronto, OntarioAges 18 years+ - NCT06307249RecruitingPhase 1
Precision therapy for solid tumors targeting CDK4/6 and VEGF
This trial tests a combination of two targeted drugs for advanced solid tumors like colorectal, lung, breast, and genitourinary cancers. The goal is to see if blocking certain proteins and a long RNA molecule can slow tumor growth.
Tripoli, North LebanonAges 18 years+ - NCT06425874Recruiting
Study on how social factors affect well-being after breast surgery
This study looks at how things like income, education, and support systems affect the quality of life and emotional well-being of younger women (ages 18-50) after breast cancer surgery. The goal is to better understand and address these factors.
Guangzhou, GuangdongAges 18–50 - NCT05720260RecruitingPhase 2
Test immunotherapy plus hormone therapy and an AKT blocker
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
TaipeiAges 20 years+ - NCT07826338Recruiting
Mobile app support for breast cancer patients starting chemotherapy
This study tests a smartphone app that provides support and information to women with breast cancer who are starting chemotherapy for the first time. The app may help manage symptoms and improve your experience during treatment.
Izmir, İzmirAges 18 years+ - NCT06472583RecruitingPhase 2
Immunotherapy and radiation before breast cancer surgery
This trial tests giving immunotherapy combined with a precise, high-dose radiation boost before surgery for HER2-negative breast cancer. The goal is to see if this approach can improve outcomes, especially for cancers that are more advanced or have spread to a few other spots in the body.
GliwiceAges 18 years+ - NCT07803081Recruiting
Radiotherapy after breast surgery without lymph node biopsy
This study looks at how well radiation therapy works for women with early-stage breast cancer who had breast-conserving surgery but did not have their underarm lymph nodes removed. It aims to understand long-term outcomes and help guide future treatment decisions.
SeoulAges 19 years+ - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT07796880RecruitingPhase 2
Study of a new drug with hormone therapy before breast cancer surgery
This trial tests a new drug called culmerciclib when given with hormone therapy before breast cancer surgery. The goal is to see if this combination can shrink tumors and improve outcomes for patients with hormone-receptor-positive, HER2-negative breast cancer.
Guangzhou, GuangdongAges 18–70 - NCT07702708Recruiting
AI predicts chemotherapy response in HR+/HER2- breast cancer
This trial uses AI to analyze your pre-treatment MRI and predict how well your tumor will respond to chemotherapy before surgery. It is for people with HR+/HER2- breast cancer who need chemo before their operation.
Fuzhou, FujianAges 18 years+ - NCT04289935Recruiting
Vacuum biopsy before surgery to check treatment response
This trial studies a special vacuum-assisted biopsy taken just before breast surgery to see how well pre-surgery (neoadjuvant) chemotherapy worked. It may help doctors understand whether patients truly had a complete or near-complete response on scans, which can guide next steps.
SalzburgAges 18 years+ - NCT07676461Recruiting
Microbiome study in advanced cancer patients starting immunotherapy
This study looks at the bacteria in your mouth, gut, and tumors to see if they affect how well first-line immunotherapy works. It is for people with advanced stomach, colorectal, breast, cervical, or head-and-neck cancer.
Bogotá, Bogota D.C.Ages 18 years+ - NCT06697938Recruiting
Chemo plus radiation vs. chemo alone for locally advanced breast cancer
This trial compares two treatments for locally advanced breast cancer: chemotherapy before surgery plus radiation, versus chemotherapy before surgery alone. The goal is to see which approach works better for this specific type of cancer.
Chengdu, SichuanAges 18–70 - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT07574671Recruiting
Ketogenic Diet Study for Early-Stage Breast Cancer
This study tests whether a ketogenic diet (high fat, low carb) can help change the environment around breast cancer tumors in ways that might slow cancer growth. You'll follow the diet for several months while researchers monitor your health and take measurements.
San Antonio, TexasAges 18 years+ - NCT06276868RecruitingPhase 2
Darsilide plus hormone therapy and double antibody for breast cancer
This trial tests if adding a new drug (darsilide) to standard hormone therapy and two antibodies (trastuzumab and pertuzumab) before surgery can improve outcomes for women with HR-positive, HER2-positive breast cancer that hasn't spread.
Henan, HenanAges 18–70 - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75
Hear when a new Inflammatory Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for inflammatory breast cancer?
- Yes. Clin2 currently lists 332 recruiting inflammatory breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a inflammatory breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a inflammatory breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.